Xhosa
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Iintlobo zeemveliso
iveliso ezifakiwe
Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health

Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health
I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso

I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso
I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango

I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango
I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers

I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers

I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic

I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 ye-SARM enamandla kwiZakhiwo zeMuscle, iiNgeniso zamandla, kunye ne-Myostatin Inhibition

I-YK-11 ye-SARM enamandla kwiZakhiwo zeMuscle, iiNgeniso zamandla, kunye ne-Myostatin Inhibition
I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba

I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba
I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa

I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa
0102030405
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers

I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers

Ixabiso elikhethiweyo:USD 50-60/kg

  • Igama lemveliso Dabrafenib
  • Inombolo yeCAS. 1195765-45-7
  • MF I-C23H20F3N5O2S2
  • MW 519.561
  • EINECS 1592732-453-0
  • Ukuxinana 1.443
  • Indawo yokubilisa 653.726 °C kwi-760 mmHg
Qhagamshelana nathi
iinkcukacha zemveliso

Inkcazo eneenkcukacha

I-Dabrafenib yi-oral bioavailable inhibitor ye-B-raf (BRAF) protein kwaye isetyenziswa njengeyeza lokulwa nomhlaza. Ijolise ngokukhethekileyo kwimihlaza eyayanyaniswa noguqulelo oluguquliweyo lwejini ye-BRAF. Eli nqaku liphonononga indlela yokusebenza, imiqondiso yeklinikhi, kunye nokusetyenziswa kwe-dabrafenib kunyango lwemihlaza eyahlukeneyo.

I. Ukuqonda iDabrafenib:
A. Inhibitor ye-B-raf (BRAF) iprotheni
B. Inkqubo yokwenza: Ukuthintela ukubonakaliswa kweprotheyini engaqhelekanga kunye nokulawula ukukhula kweeseli

17159473034104h3

II. Iimpawu zoNyango:

A. Unyango lweMonotherapy:

Imelanoma engachaswanga okanye imetastatic ene-BRAF V600E ukuguqulwa

B. Unyango oludityanisiweyo kunye netrametinib:

I-BRAF V600E-positive engachaswanga okanye imetastatic melanoma

Umhlaza wemiphunga weMetastatic ongeyonxalenye encinci

Umhlaza we-thyroid ye-Metastatic anaplastic

Amathumba aqinileyo angenakuchaswa okanye e-metastatic


III. Indlela yokwenza:

A. Ukubophelela okukhethiweyo kunye nokuthintelwa kwe-B-raf

B. Ukuvinjelwa kwe-tumor cell proliferation kunye ne-BRAF gene eguqulweyo


IV. Unyango kuMhlaza weNdlala:

A. Uhlobo oluthile lomhlaza wedlala lengqula oluye lwanwenwela kwizihlunu ezikufutshane okanye kwamanye amalungu omzimba

B. Unyango lwangaphambili (s) ukuxhathisa


Udidi lwe-V. Kinase Inhibitor:

A. I-Dabrafenib njengelungu le-kinase inhibitors

B. Ukuthintela isenzo seprotheyini esingaqhelekanga ukuthintela ukuphindaphindeka kweeseli zomhlaza


I-Dabrafenib lunyango ekujoliswe kulo olusetyenziswa kunyango lwe-BRAF-mutated cancers. Njenge-inhibitor yeprotheni ye-B-raf (BRAF), ijolise ngokukhethiweyo kwiiseli zethumba eziqulethe i-BRAF gene eguqulweyo, inqanda ukwanda kwazo. I-Dabrafenib iboniswa kwi-melanoma engabonakaliyo okanye i-metastatic, umdlavuza we-cell lung ongeyena omncinci, umhlaza we-thyroid ye-anaplastic, kunye ne-tumor eqinile engabonakaliyo okanye e-metastatic. Unyango oludityanisiweyo kunye ne-trametinib yandisa ngakumbi izicelo zayo. Ngokuqonda utshintsho oluthile lwemfuzo kwiiseli zomhlaza, unyango ekujoliswe kulo njenge-dabrafenib ludlala indima ebalulekileyo ekuphuculeni iziphumo zonyango kunye nokuthintela ukusasazeka kweeseli zomhlaza.

Inkcazo

1715947563669qd1